FFO
PTCT icon

Fortitude Family Office’s PTC Therapeutics PTCT Stock Holding History

Fortitude Family Office’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.12K Buy
75
+43
+134% +$3.1K ﹤0.01% 985
2026
Q1 		$2.18K Buy
32
+7
+28% +$496 ﹤0.01% 1258
2025
Q4 		$1.9K Buy
25
+8
+47% +$581 ﹤0.01% 1202
2025
Q3 		$1.04K Sell
17
-1
-6% -$52 ﹤0.01% 1529
2025
Q2 		$879 Buy
+18
New +$854 ﹤0.01% 1578

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fortitude Family Office's PTCT Position: Q2 2026 in Review

Fortitude Family Office increased its PTC Therapeutics (PTCT) stake by 134% in Q2 2026, buying an estimated $3.1K and bringing the position to 75 shares worth $6.12K. The position accounts for ﹤0.01% of the portfolio, ranked #985.

Fortitude Family Office first reported a position in PTCT in Q2 2025 and has held it in 5 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Fortitude Family Office held 75 shares of PTC Therapeutics worth $6.12K as of Q2 2026.
  • Fortitude Family Office bought 43 PTC Therapeutics shares in Q2 2026, an estimated $3.1K.
  • PTC Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #985 holding.
  • Fortitude Family Office first reported a position in PTC Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.